EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Predicting Right Ventricular Failure After Left Ventricular Assist Device Implant: A Novel Approach

Carissa E Livingston iD, Dale Kim, Lacey Serletti, Andrea Jin, Sriram Rao, Michael V Genuardi, Eliot G Peyster iD

ESC Heart Failure · 01.06.2025 · 12 (3) · 1916-1931

DOI: 10.1002/ehf2.15200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 20.01.2025. Verfasst von Carissa E Livingston und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Ventricular Dysfunction, Right, Heart Failure, Ventricular Function, Right. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, W. W. Smith Charitable Trust, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Right ventricular (RV) failure (RVF) after left ventricular assist device (LVAD) implant is an important cause of morbidity and mortality. Modern, data-driven approaches for defining and predicting RVF have been under-utilized.

Methods

Two hundred thirty-two patients were identified with a mean age of 55 years; 40 (17%) were women, 132 were (59%) Caucasian and 74 (32%) were Black. Patients were split between Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) Classes 1, 2 and 3 (25%, 38% and 34%, respectively). Within this group, ‘provisional RVF’ patients were identified, along with ‘no RVF’ patients. ‘No RVF’ patients were defined as patients who never demonstrated more than moderate RV dysfunction on a post-LVAD transthoracic echocardiogram (TTE) (ordinal RV function <3), never required an RV assist device (RVAD), were not discharged on sildenafil and were not on a pulmonary vasodilator or inotropic medication at 3 months after LVAD implant. In total, n = 67 patients were defined as ‘no RVF’. The remaining patients represented the ‘provisional RVF’ population (n = 165). Extensive electronic health records queries yielded >1200 data points per patient. Using <1 and >1 month post-LVAD time windows motivated by established, expert-consensus definitions of ‘early’ and ‘late’ post-implant RVF, unbiased clustering analysis was performed to identify hidden patient ‘phenogroups’ within these two established RVF populations. Clusters were compared on post-implant clinical metrics and 1 year outcomes. Lastly, pre-implant metrics were used to generate models for predicting post-implant RVF phenogroup.

Results

Within the ‘early RVF’ time window, distinct ‘well’ and ‘sick’ patient phenogroup clusters were identified. These clusters had similar RV function and pulmonary vasodilator usage during the first month after LVAD but differed significantly in heart failure therapy tolerance, renal (P < 0.001) and hepatic (P = 0.013) function, RVAD usage (P = 0.001) and 1 year mortality (P = 0.047). Distinct ‘well’ and ‘sick’ phenogroups were also identified in the ‘late RVF’ time window. These clusters had similar RV function (P = 0.111) and RVAD proportions (P = 0.757) but differed significantly in heart failure medication tolerance, pulmonary vasodilator usage (P = 0.001) and 1 year mortality (P < 0.001). Prediction of phenogroup clusters from the ‘early RVF’ population achieved an area under the receiver operating characteristic curve (AUROC) of 0.84, with top predictors including renal function, liver function, heart rate and pre-LVAD RV function.

Conclusions

Distinct, potentially predictable phenogroups of patients who have significantly different long-term outcomes exist within consensus-defined post-LVAD RVF populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesVentricular Dysfunction, RightHeart FailureVentricular Function, RightRegistriesHeart VentriclesHumansFemaleMaleMiddle AgedRetrospective StudiesEchocardiographyFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

LVADRVADheart failureright ventricle

Autor:innen und Institutionen

  • Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Monash University Victorian Heart Institute, Melbourne, Victoria, Australia.
  • Division of Cardiology, Department of Medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Cardiovascular Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Carissa E Livingston, Eliot G Peyster

Förderung

  • NHLBI NIH HHS
  • W. W. Smith Charitable Trust
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Livingston, C. E., Kim, D., Serletti, L., Jin, A., Rao, S., Genuardi, M. V., & Peyster, E. G. (2025). Predicting Right Ventricular Failure After Left Ventricular Assist Device Implant: A Novel Approach. ESC Heart Failure, 12(3), 1916-1931. https://doi.org/10.1002/ehf2.15200

Vancouver

Livingston CE, Kim D, Serletti L, Jin A, Rao S, Genuardi MV, et al. Predicting Right Ventricular Failure After Left Ventricular Assist Device Implant: A Novel Approach. ESC Heart Failure. 2025;12(3):1916-1931. doi:10.1002/ehf2.15200

BibTeX
@article{Livingston2025,
  author = {Livingston, Carissa E and Kim, Dale and Serletti, Lacey and Jin, Andrea and Rao, Sriram and Genuardi, Michael V and Peyster, Eliot G},
  title = {Predicting Right Ventricular Failure After Left Ventricular Assist Device Implant: A Novel Approach},
  journal = {ESC Heart Failure},
  year = {2025},
  volume = {12},
  number = {3},
  pages = {1916--1931},
  doi = {10.1002/ehf2.15200}
}
Kostenlos starten →